Cediranib in combination with olaparib is in clinical development for the treatment of platinum resistant recurrent (PRR) ovarian cancer in patients who have received no more than three prior treatments. Ovarian cancer includes epithelial ovarian cancer (EOC), primary peritoneal cancer and fallopian tube cancer, with EOC being the most common type. Symptoms of ovarian cancer include bloating, pain and frequent urination. Platinum-based chemotherapy is the main type of initial treatment used in ovarian cancer. However, over time some patients may become platinum-resistant whereby this treatment stops working and disease progresses. For these patients, further treatments are needed.
Cediranib with olaparib for previously treated platinum resistant recurrent ovarian cancer
Cediranib in combination with olaparib is in clinical development for the treatment of platinum resistant recurrent (PRR) ovarian cancer in patients who have received no more than three prior treatments.